MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

November 22, 2026 · Pharmaceuticals

Process Validation When PPQ Batches Fail: Lessons from FDA's LGM Pharma Warning Letter

By Mussarat Fatima

PharmaceuticalsGMPQuality Assurance
Process Validation When PPQ Batches Fail: Lessons from FDA's LGM Pharma Warning Letter

Process validation is where a manufacturer proves, with data, that its process will reliably make a drug that meets specification every time. So when a process performance qualification (PPQ) batch fails, a company faces one of the most consequential decisions in pharmaceutical quality: stop and investigate the root cause, or press on toward commercial release. On 2 November 2026, the United States Food and Drug Administration (FDA) issued a warning letter to LGM Pharma Solutions, LLC that shows, in detail, what happens when a firm gets that decision wrong.

The letter is useful to anyone who runs or oversees validation, because it names the exact failure modes inspectors look for: a PPQ batch that failed specification, a validation report approved anyway, critical in-process attributes left without limits, and commercial batches released even though they carried the same root cause seen in the validation batches. This article walks through what the FDA found, what Health Canada expects under GUI-0029, and the practical steps to take when a validation batch returns an out-of-specification (OOS) result. For the planning document that sits above all of this, see our guide to building a validation master plan.

Executive summary

The LGM Pharma warning letter (CDER reference 320-27-18) followed a May 2026 inspection of the firm's Irvine, California site. FDA cited two CGMP regulations that matter for every validation programme: 21 CFR 211.192 (failure to thoroughly investigate batch failures) and 21 CFR 211.100(a) (failure to establish adequate production and process control procedures). The key takeaways are below.

  • A PPQ batch that fails specification is a signal that the process is not yet in a state of control, not a paperwork item to be closed with a conclusion that the batch was never released.
  • A validation report must not be approved over a confirmed OOS without a documented, scientifically sound justification and a completed investigation.
  • Critical quality attributes seen to vary during PPQ, such as particle size distribution and tablet thickness, need defined specifications before commercial manufacturing, not after.
  • If commercial batches share the same root cause found in validation batches, releasing them is an enforcement risk and a recall risk.
  • FDA recommended the firm engage a qualified consultant under 21 CFR 211.34 and complete a six-system audit, a recurring pattern in 2026 CGMP letters.

What is process performance qualification (PPQ)?

Process performance qualification is the stage of process validation where a firm confirms, on commercial-scale batches, that its process reproducibly makes product meeting all quality attributes. It is the formal demonstration that the process is in a state of control before commercial distribution begins. In FDA's lifecycle model, PPQ sits inside Stage 2, Process Qualification. Successful PPQ is a precondition for routine commercial supply, and it is followed by Stage 3, continued process verification, which monitors the process for the rest of its life.

Why it matters: PPQ is the point where design intent meets manufacturing reality. If a PPQ batch fails, the process has told you something. The regulatory question is never whether the failed batch was shipped. It is whether the process can be trusted to make the next hundred batches.

What the LGM Pharma warning letter actually found

According to the FDA warning letter, the firm's process validation protocol required passing results for three batches. During PPQ, one batch failed to meet the specification for one of the active ingredients. The process validation report was then approved despite that confirmed OOS failure. The report itself stated that the failure could not be adequately investigated because the remaining sample had been consumed by tablet manufacturing, and no scientific rationale was recorded for concluding that validation was acceptable anyway.

FDA also found that in-process critical quality attributes were not adequately controlled. The validation report noted variability in both the particle size distribution of an intermediate and in tablet thickness, and recorded results outside the firm's proposed ranges, yet no specifications were established for those attributes. On top of that, several PPQ batches returned OOS assay results at stability timepoints. The firm concluded these had no quality impact because the batches were not distributed. FDA's position was blunt: multiple OOS results during PPQ demonstrate a process that is not in a state of control.

The most damaging finding was the link to commercial supply. The firm's OOS investigations for commercial batches listed the same root causes identified for the validation batches, yet it continued to release commercial product. FDA cited this under 21 CFR 211.192 and noted the firm did not take timely market action after a confirmed OOS retest, and left an OOS investigation open without scientific justification. One commercial batch was ultimately recalled. For the mechanics of a compliant batch-failure investigation, see our explainer on 21 CFR 211.192 batch failure investigations.

Can you release commercial batches after a failed PPQ?

Short answer: not until the failure is explained and the process is shown to be in control. A PPQ failure that is not fully investigated leaves you without the evidence that validation is meant to provide. Releasing commercial batches in that state means you are shipping product from a process you have not proven, and if those batches share the validation batch's root cause, you are knowingly distributing product with an unresolved quality risk. That is precisely the chain FDA built against LGM Pharma. The lawful path is to stop, investigate to a true root cause, correct the process, and requalify before commercial release.

The validation lifecycle: FDA stages and Health Canada GUI-0029

Canadian manufacturers answer to Health Canada's Guide to validation, drugs and supporting activities (GUI-0029), read alongside the Good Manufacturing Practices guide (GUI-0001). FDA's framework comes from its 2011 guidance, Process Validation: General Principles and Practices. The two systems line up closely, which is why an FDA finding translates cleanly into a Canadian expectation.

Lifecycle stageFDA Process Validation (2011)Health Canada expectation (GUI-0029 / GUI-0001)
Stage 1: Process DesignDefine the commercial process using development and scale-up knowledge, including identifying critical quality attributes and process parameters.Design and development data expected to support the chosen validation approach and justify critical parameters.
Stage 2: Process Qualification (PPQ)Confirm, on commercial-scale batches, that the process is reproducible and in a state of control before commercial distribution.Prospective process validation on consecutive commercial-scale batches against predetermined acceptance criteria before routine supply.
Stage 3: Continued Process VerificationOngoing monitoring of intra-batch and inter-batch variation across the product lifecycle.Ongoing review, trending and revalidation when changes or adverse trends occur.

From FDA citation to Health Canada requirement

One of the most useful exercises after any FDA warning letter is to map each U.S. citation to the equivalent Canadian requirement. The table below does that for the LGM findings.

FDA citation in the LGM letterWhat it requiresCanadian equivalent
21 CFR 211.100(a)Written production and process control procedures designed to assure identity, strength, quality and purity.Food and Drug Regulations, Part C, Division 2 (Good Manufacturing Practices); process validation expectations in GUI-0001 and GUI-0029.
21 CFR 211.192Thorough investigation of any batch or component failure, whether or not the batch was distributed.Division 2 deviation and investigation requirements; Health Canada's expectation of documented, root-cause investigations.
21 CFR 211.34Engage a consultant with sufficient education, training and experience, and keep records of their qualifications.No identical clause, but Health Canada expects qualified personnel and accepts third-party support during remediation.

What to do when a PPQ batch fails: five steps

When a validation batch returns an OOS result, a disciplined sequence protects both the product and the firm.

  1. Secure the evidence first. Retain enough of the sample and the batch record to allow a full investigation. LGM could not investigate because the material had been consumed. Build sample retention into the PPQ protocol so a failure can always be examined.
  2. Run a full OOS investigation. Follow FDA's OOS guidance and your own SOP through laboratory and manufacturing phases. If a laboratory cause is not conclusively proven, extend the investigation into the process. Our guide to OOS invalidation, retesting and human error explains where firms most often go wrong.
  3. Do not approve the report over an open failure. A validation report cannot conclude success while a confirmed OOS sits unexplained. If the failure is real, the honest conclusion is that validation has not been met.
  4. Set the specifications you were missing. If attributes such as particle size or tablet thickness varied beyond proposed ranges, define and justify limits before you qualify. Unspecified critical attributes are a standing citation.
  5. Correct, then requalify. Fix the process or control, document the CAPA, and repeat PPQ. Only consecutive successful batches against predetermined criteria support commercial release. If commercial product was already shipped, assess impact and take market action without delay. See our FDA warning letter production restart playbook for the remediation sequence.

PPQ compliance checklist

  • A written validation master plan defines the PPQ approach, acceptance criteria and the number of batches.
  • Critical quality attributes and critical process parameters are identified, with specifications and justified ranges.
  • Sample retention is sufficient to investigate any failure, built into the protocol.
  • An OOS SOP covers validation batches, with defined laboratory and manufacturing phases.
  • The validation report cannot be approved while a confirmed OOS is open and unexplained.
  • A documented link check confirms no commercial batch shares an unresolved validation root cause.
  • Continued process verification trends intra-batch and inter-batch variability after launch.

Common mistakes

The first mistake is treating PPQ as a documentation exercise rather than a scientific test. A protocol that is written to pass rather than to probe will miss the variability that later causes a recall. The second is closing an OOS by attributing it to method or raw-material variability without data. LGM claimed analytical method variability but, in FDA's view, provided no supporting evidence and had not validated the method to account for that variability. If you blame the method, prove it, and fix the method.

The third mistake is a quality unit that cannot hold the line. When commercial pressure meets an open validation failure, someone has to be able to say the report is not approvable. A weak quality unit is why unexplained OOS results get signed off, and it is why our work on why CAPA keeps failing keeps returning to governance and authority, not just paperwork.

Frequently asked questions

What happens if a process validation batch fails?

A failed validation batch means the process has not yet demonstrated a state of control. You investigate the failure to a true root cause, correct the process or control, and repeat process performance qualification. Validation is not complete, and commercial distribution should not proceed, until consecutive batches meet the predetermined acceptance criteria.

Can you release commercial batches if PPQ had an OOS?

Not while the OOS is unexplained. If the same root cause could appear in commercial product, releasing those batches distributes an unresolved quality risk. FDA's LGM Pharma letter shows the agency will link a validation failure directly to commercial release decisions.

Does Health Canada require process validation?

Yes. Process validation is expected under Canadian Good Manufacturing Practices (Food and Drug Regulations, Part C, Division 2), with detailed expectations in Health Canada's GUI-0029 validation guide and the GUI-0001 GMP guide. The lifecycle logic mirrors FDA's three-stage model.

How many batches are needed for PPQ?

There is no fixed number in current FDA guidance; the count should be justified by risk and process knowledge. Many firms still use three consecutive batches as a conventional baseline, as LGM's own protocol did. The important point is that every qualifying batch must pass the predetermined criteria.

What does a confirmed OOS during validation require?

A full investigation through both laboratory and manufacturing phases, a documented root cause or a scientifically justified conclusion, CAPA, and a decision that does not approve the validation report while the failure is open. Attributing the result to method variability requires supporting data.

How do in-process attributes like tablet thickness fit in?

Attributes that influence product quality, such as particle size distribution and tablet thickness, are critical quality attributes that need defined, justified specifications. If PPQ shows them drifting outside proposed ranges, you set and justify limits before qualifying, not after.

How MFLRC can help

MF License & Regulatory Consultants (MFLRC) works with pharmaceutical, over-the-counter, natural health product and CDMO manufacturers to make validation defensible before an inspector sees it. Our pharmaceutical validation services cover validation master planning, process and equipment qualification, PPQ protocol and report review, and continued process verification design. When a validation batch fails, we support OOS investigation remediation and CAPA, and we can act as an independent reviewer of a validation programme, the kind of qualified support FDA recommends under 21 CFR 211.34.

Our audit services include mock FDA inspections and six-system audits, so you can test your validation files, your quality unit's authority and your OOS handling the way an inspector would. We also help align your Canadian GMP documentation to GUI-0001 and GUI-0029, and map any FDA finding to its Health Canada equivalent. If you are preparing a PPQ, or facing an OOS in a validation batch, we review protocols, reports and investigations before they become a finding.

Conclusion

The LGM Pharma warning letter is a clear reminder that process validation is a scientific commitment, not a formality. A PPQ batch that fails is the process telling you something, and the only safe response is to listen: secure the evidence, investigate fully, fix the cause, set the specifications you were missing, and requalify. Treating a validation failure as a contained paperwork issue is exactly how a firm ends up with a recall, a warning letter, and a mandated consultant. Build validation to find problems, and your inspection will take care of itself.

Sources and references

Downloadable Resource

PPQ Batch Failure Response Checklist

A one-page checklist for handling an out-of-specification result in a process validation batch, aligned to FDA and Health Canada expectations.

File: MFLRC-PPQ-Batch-Failure-Checklist.pdf

Share with others

Tags

Process ValidationOut-of-SpecificationCGMPWarning LettersCAPAAnnex 15RemediationPharmaceuticals